Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00CZT
|
|||
| Former ID |
DNCL002000
|
|||
| Drug Name |
Solanezumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1], [2] | |
| Company |
Eli Lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6932). | |||
| REF 2 | ClinicalTrials.gov (NCT01900665) Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo. U.S. National Institutes of Health. | |||
| REF 3 | Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.